GlassScriptPhysician profile
Bryan James Colligan
NPI 1174905350
$8,522.84
in general payments reported to CMS, 2019-2025
36 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $361 · 2021: $839 · 2022: $1,618 · 2023: $1,327 · 2024: $1,354 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,522.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,193.01 | 2019-2025 | |
| Novo Nordisk INC | $1,177.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,063.92 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $674.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Madrigal Pharmaceuticals | $514.44 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $505.95 | 2019-2025 | Ubrelvy, Vraylar |
| Exact Sciences Corporation | $472.10 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $426.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $336.59 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $255.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.18 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.48 | 2020-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $182.19 | 2019-2025 | |
| Amarin Pharma, INC. | $144.92 | 2019-2022 | |
| Astellas Pharma US INC | $124.55 | 2019-2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $117.78 | 2021 | |
| Celgene Corporation | $113.63 | 2019 | |
| Merck Sharp & Dohme LLC | $112.58 | 2019-2023 | Steglatro, Belsomra |
| Sanofi-Aventis U.S. LLC | $101.58 | 2019-2023 | |
| Organogenesis INC. | $97.98 | 2023 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $80.00 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $45.30 | 2021-2023 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $44.54 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.96 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $37.95 | 2023 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $35.33 | 2024-2025 | Gvoke Hypopen |
| Allergan, INC. | $30.57 | 2019 | |
| Verona Pharma, INC. | $17.80 | 2025 | Ohtuvayre |
| Amneal Pharmaceuticals LLC | $16.01 | 2019 | |
| Bioventus LLC | $15.94 | 2025 | Exogen Ultrasound Bone Healing System |
| Dexcom, INC. | $15.42 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2023 | Xifaxan, Trulance |
| Heraeus Medical, LLC. | $14.08 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.93 | 2021 | |
| Apria Healthcare LLC | $11.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Colligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.